Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

For viral vector-based immunotherapies, confirming transgene expression alone is insufficient for regulatory submissions. A functional bioassay that measures the potency and mechanism of action, such as Natural Killer (NK) cell-mediated cytotoxicity, is required to demonstrate product consistency and biological activity. Franklin Biolabs develops and qualifies robust, phase-appropriate cytotoxicity assays for plasmid and viral vector programs (AAV, Lentivirus, Adenovirus). This provides data packages suitable for Investigational Medicinal Product Dossier (IMPD) submissions to agencies including the MHRA, supporting an 18-24 month timeline to IND.

Defining Functional Potency for Vector-Based Immunotherapies

Standard analytical methods can confirm the physical characteristics of a viral vector: titer, purity, and capsid integrity. These methods cannot, however, confirm that the genetic payload, once delivered, produces a biologically active protein capable of executing its intended function. For immunotherapies, this functional gap presents a tangible risk to program timelines.

A well-designed cytotoxicity bioassay provides this missing data. It serves as a direct measure of the product’s mechanism of action, linking the physical vector to a quantifiable biological outcome. This component is a standard expectation for CMC packages submitted to regulatory bodies.

Assay Development for Regulatory Compliance

Our scientific team designs cytotoxicity assays tailored to the specific mechanism of your therapeutic candidate. The process is built to withstand regulatory scrutiny, ensuring the final assay is robust, reproducible, and suitable for its intended purpose, whether for characterization or as a GxP lot release test. Accelerated characterization for rapid product validation is achieved through a structured approach.

Key technical considerations include:

• Selection of appropriate target cell lines and effector cells (primary NK cells or cell lines like NK-92).

• Optimization of effector-to-target (E:T) cell ratios.

• Method selection: classic chromium release, fluorescence-based methods, or impedance-based real-time analysis.

• Qualification of the assay according to phase-appropriate GxP principles for inclusion in UK and EU regulatory filings.

Linking Vector Performance to Biological Function

The development of advanced viral vectors requires equally advanced analytical tools. The ability to overcome vector packaging limitations to ensure expression of a functional protein is a known technical hurdle (PMID: 19257851). A cytotoxicity assay directly verifies the success of such engineering by confirming the expressed protein is present and functionally potent.

Understanding vector immunogenicity is also a central component of a successful program. Transgene products delivered by vectors can elicit complex immune responses that impact efficacy (PMID: 19441963). A functional bioassay provides a stable method to ensure that each manufacturing lot possesses the same specific biological activity before administration. This provides a baseline for interpreting in vivo immunological data and is part of building a data package that supports a successful IND submission, a process our teams have navigated with a 100% success rate since 2019 for programs initiated before the Franklin Biolabs brand launch in 2024.